Cadila Healthcare can begin a new bull run on technical levels......analysis is also backed by news of Virafin(an antiviral produced by Cadila Healthcare) being given emergency approval for treatment of moderate COVID-19 patients.
Volume has also increased drastically.
Cadila has also given closing above a trendline which was previously acting as resistance for the price to move up.
Bilgiler ve yayınlar, TradingView tarafından sağlanan veya onaylanan finansal, yatırım, işlem veya diğer türden tavsiye veya tavsiyeler anlamına gelmez ve teşkil etmez. Kullanım Şartları'nda daha fazlasını okuyun.